Alzheimer’s Disease

Rather than studying people diagnosed in clinic, this study looked at the genes of 12,509 people whose brains were examined after death, so the pathology was known for certain. It is the largest such analysis so far. APOE was linked to Alzheimer's and related pathologies but not to blood vessel damage, and twelve regions were tied to particular lesions, seven of them new. Several known Alzheimer's and Parkinson's variants were also linked to Lewy body pathology.

Genome studies have linked more than 75 genetic variants to Alzheimer's and dementia, raising hopes that a combined "polygenic risk score" could flag people at higher risk. But most scores were built mainly from people of European ancestry. This study tested several scoring methods in more than 6,000 African American, Chinese, Hispanic, and White participants and found performance varied by approach and ancestry. The work is an important step toward fair, accurate genetic risk prediction that works across diverse populations.

APOE is the strongest common gene affecting late-onset Alzheimer's, and carrying two copies of its ε4 version raises risk most. Earlier reports suggested the effect was unusually large in Japanese people (over 20-fold). This meta-analysis reappraised the data and found the risk from two ε4 copies is about 12 to 15 times higher than the common ε3 form, similar to what is seen in people of European descent. Getting these numbers right matters for accurate genetic counseling and for fairly comparing Alzheimer's risk across populations.

Researchers in China built a new mouse model carrying the human PSEN1 V97L change, which is common in Chinese families with inherited Alzheimer's disease. Unlike older models that flood the animal with extra protein, this one places the human change in its natural position in the genome. By four months the mice already showed inflammation from activated microglia, before any amyloid had built up. Memory problems, loss of nerve branches and myelin damage followed by eight months, pointing to inflammation as an early event.

APOE4 is the strongest common genetic risk factor for Alzheimer's disease, and it works partly through a protein called ABCA1 that helps "fatten up" APOE so it can clear debris from the brain. Drugs that switch on ABCA1 (LXR agonists) help in animal models but have caused fatty-liver side effects in people. This study screened many LXR-activating compounds to find ones that boost the beneficial brain pathway without the liver problem, an early step toward APOE-targeted Alzheimer's therapies for people at genetic risk.

APOE4 is the strongest common genetic risk factor for Alzheimer's disease. Working in mice that carry human APOE4, researchers reduced a microglial gene called Lilrb4a, either by deleting it or by using an antisense drug of the kind already used in people. Both approaches cut amyloid plaque build up in the cortex and reduced amyloid in blood vessel walls, without changing how much amyloid was produced. The microglia appeared to switch into a state better at clearing amyloid away.

New Alzheimer's drugs in Australia require APOE genotype testing, raising the question of how to share such results safely. This pilot tested a video-based protocol for disclosing APOE status to 15 cognitively healthy adults (with a family history of dementia) over several online sessions including mood and readiness checks. All completed it with no adverse events; anxiety actually fell after disclosure, and any rise in low mood stayed minor. The study suggests remote, structured genetic disclosure can be feasible and well tolerated, helping widen access to counseling.

This preprint, which has not yet been through peer review, maps genetic risk genes for Alzheimer's disease, Lewy body dementia and frontotemporal dementia onto a large atlas of where genes are switched on across organs, brain regions and cell types. All three diseases converged on nerve cells, while Alzheimer's risk genes were also concentrated in immune and liver related gene groups. The approach offers a way of asking not just which genes raise risk but where they act.

Certain variants of the TREM2 gene (R47H and R62H) raise Alzheimer's risk by changing how the brain's immune cells (microglia) respond to amyloid, while a protective variant in a related gene, CD33, blunts that risk. Studying human postmortem brain, this UK team showed the two genes interact: the protective CD33 form normalized amyloid differences in TREM2-variant carriers. The variants also shifted microglial gene activity, with R47H dampening protective responses. Untangling how these risk genes work together clarifies why they raise risk and where treatments might intervene.

Genes can be read in several different ways to make slightly different versions of a protein, a process called splicing. This study introduces a more sensitive way of measuring those versions and applies it to Alzheimer's genes across large public datasets. It establishes which forms of APP, the gene that makes amyloid precursor protein, are the main ones, and finds one form that appears mainly in immune cells. Fine detail like this can shape which version a future drug should target.

This review asks whether faulty gene splicing, the editing step that decides which version of a protein a cell makes, is a cause of Alzheimer's disease or a consequence of it. The authors examine how splicing goes wrong in key genes including APP, MAPT and PSEN1 and PSEN2, and how aging, inflammation and cellular stress disturb the machinery that does the editing. They argue the evidence points both ways, and set out what research would settle the question.

Researchers turned human stem cells into the type of nerve cell that is lost early in Alzheimer's disease, comparing cells carrying two copies of the APOE4 risk gene against otherwise identical cells carrying APOE3. The APOE4 cells matured faster at first but were slower to form proper connections between neurons, and they responded differently to an inflammatory signal. Because the cells were identical apart from that one gene, the differences can be attributed to APOE4 itself.

Some of a person's Alzheimer's risk is inherited, and researchers are still mapping which gene variants contribute. This case-control study compared 95 Alzheimer's patients with 97 healthy people, testing several common variations in the SNCA gene (which makes the protein alpha-synuclein) using statistics and machine learning. A few variants were more frequent in patients, hinting they may nudge up disease risk. Findings like these help build the genetic risk picture of Alzheimer's, though they need confirmation in larger and more diverse groups.

When Alzheimer's begins before age 65, doctors often look for a genetic cause. This report describes a 59-year-old woman with biomarker-confirmed early-onset Alzheimer's whose standard genetic tests (APP, APOE, PSEN1) were negative, but who carried a variant in CHMP2B, a gene involved in the cell's waste-recycling system and usually linked to frontotemporal dementia. The authors suggest this variant may act as a "modifier" influencing her disease. Cases like this widen understanding of the genes that can shape early-onset Alzheimer's.

Most searches for Alzheimer's risk genes look at single-letter DNA changes, but the genome also contains short repeated sequences that are harder to study. Using data from about 330,000 people, this study systematically tested these "short tandem repeats" and found 15 regions linked to Alzheimer's risk, including some not clearly seen before. Mapping these overlooked kinds of genetic variation deepens understanding of the inherited component of Alzheimer's and points to new biological mechanisms behind the disease.

Does the number of APOE ε4 gene copies affect how fast mild cognitive impairment progresses to Alzheimer's dementia? Using 1,115 participants from the ADNI study, researchers tracked time to conversion by ε4 count. Median dementia-free survival was far longer for people with no ε4 copies than for those with one or two, and each additional copy raised the conversion risk substantially even after accounting for memory-region size and baseline cognition. The authors frame ε4 dose as a useful marker of progression risk, helpful for prognosis and trial planning.

This is the largest genetic study of Alzheimer's disease and related dementias to date, combining data from about 128,000 patients and 850,000 people without dementia. It confirms 91 regions of the genome linked to risk, 16 of them new. A score combining these regions, leaving out APOE, was tied mainly to Alzheimer's changes rather than other dementias, and people in the top tenth of scores had roughly twice the chance of extensive tangle and plaque pathology at death.

A person's other genes shape how Alzheimer's unfolds, but most mouse models use a single genetic background. Researchers bred Alzheimer's-model mice onto a different genetic strain and showed they develop amyloid in blood-vessel walls, vascular dysfunction, and white-matter damage that more closely mirror human disease, and that crossing in different APOE gene variants altered the severity. The model gives researchers a more realistic, genetically varied tool for studying how inherited factors influence the blood-vessel side of Alzheimer's.

People with autosomal dominant Alzheimer's carry a mutation (in PSEN1, PSEN2, or APP) that makes the disease near-certain, yet the age and way it strikes still vary. To find inherited factors that modify that course, this genome-wide study compared 101 people with these mutations against thousands of controls and identified three genetic regions tied to risk, checking their effects on blood and spinal-fluid markers, brain imaging, and age at onset. Genetic modifiers like these help explain why the same mutation plays out differently and point toward targets for therapy.

Because the APOE ε4 gene so strongly drives Alzheimer's, finding other genes that counteract its effects could reveal treatments. This large study ran a genome-wide search separately in ε4 carriers and non-carriers (nearly 448,000 people) and combined it with detailed brain cell-type data to pinpoint genes acting through specific cells, with oligodendrocytes especially prominent in carriers. Several of the genes were druggable, and the team flagged existing compounds that might be repurposed depending on a person's ε4 status. It is a step toward genetically tailored Alzheimer's therapies.

The locus coeruleus, a small brainstem hub, is among the first regions affected in Alzheimer's. This study examined the nerve-fiber tract linking it to the entorhinal cortex (a memory area) in people carrying the PSEN1-E280A mutation that causes inherited Alzheimer's. Weaker tract integrity was tied to higher tau buildup and poorer memory in mutation carriers, with tau and amyloid partly explaining the memory link as the disease advanced. The findings mark this tract as an early vulnerability worth tracking, potentially useful for timing treatment in autosomal dominant Alzheimer's.

The Dutch mutation in the APP gene causes an inherited condition in which amyloid builds up in the blood vessels of the brain. Studying mice carrying this change, researchers found that loose, non fibrous clumps of amyloid, rather than classic dense plaques, disturbed the way nerve endings release their chemical signals, and did so without detectable inflammation. The finding supports the view that smaller, soluble forms of amyloid may do more damage to communication between nerve cells than plaques do.

Doctors in China report a 43 year old woman with three years of worsening memory problems, brain scans showing widespread shrinkage, and spinal fluid results typical of Alzheimer's disease. Gene sequencing found a previously undescribed change in PSEN1, the gene most often responsible for autosomal dominant early onset Alzheimer's disease. Reports like this gradually build the catalog of which specific changes cause disease, which is what allows a laboratory to tell a family whether a variant found in testing is meaningful.

Some people who carry a strong familial-Alzheimer's mutation (in the PSEN1 gene) develop the disease later than expected, hinting at protective "modifier" genes. Researchers found that lower activity of a gene called SH3RF3 was linked to delayed Alzheimer's onset in PSEN1 carriers, and in lab studies reducing SH3RF3 calmed the inflammatory responses of microglia (the brain's immune cells). The finding points to a new potential drug target and helps explain why the same inherited mutation can affect family members differently.

The R47H change in the TREM2 gene is one of the strongest genetic risk factors for late-onset Alzheimer's. Using mice carrying this human variant, researchers found it disturbs fat and metabolite signaling not only in the brain but along a liver-blood-brain axis, with the earliest changes appearing in the liver and blood. The results suggest this Alzheimer's-risk gene has body-wide metabolic effects, and that blood-based measures might one day help track its influence.